P341 Pancreatic status and enzyme usage in the age of CFTR modulator treatment

Approximately 85% of patients with CF are pancreatic insufficient (PI), requiring enzyme replacement therapy (PERT) all fat-containing food & drinks. PERT is commenced based on clinical signs PI such as steatorrhea poor weight gain. Faecal elastase (FE) tests used to confirm PI. This audit was conducted see if adults at a UK centre have FE result, check usage genotype CFTR modulator treatment. Data collected using patient medical records in January 2023. included number patients, date test result/s, genotype, enzymes missed (patient report), when commenced. 88 were (50% DF508 homozygous, 44% heterozygous), 76% PERT. 36 had least one test; 18 which severe PI, 3 moderate-mild insufficiency, and 15 sufficient (PS). Only 6 result pre post starting therapy; 1 showed change from severely 12 who homozygous 11 (10 modulator, post), (post treatment). 41 report they miss do not get modulators). 100% adherence. take The majority adult this done PERT, almost half the cohort reporting missed, indicating high likelihood rates Due low performing there data indicate modulators status FE, however 11% since therapy.